Empagliflozin in acute Myocardial Infarction


The EMpagliflozin in acute MYocardial Infarction (EMMY) trial was presented today by former DTU Research Fellows, Dr Harald Sourij and Dr Abderrahim Oulhaj, at the European Society of Cardiology (ESC) Congress in Barcelona with simultaneous publication in the European Heart Journal.
EMMY aimed to investigate whether empagliflozin treatment given in addition to guideline recommended post-MI therapy, and initiated within 72 hours after percutaneous coronary intervention in people with a large acute myocardial infarction, with or without diabetes, would result in a larger decline in NT-proBNP and a larger improvement in ejection fraction.
The results showed that the NT-proBNP reduction observed after an acute myocardial infarction was significantly greater after 26 weeks of empagliflozin treatment, compared with placebo, with significantly greater improvements in cardiac function and structural echocardiographic parameters. No significant safety concerns were noted.
The accompanying editorial, entitled "Putting the Puzzle Together", stated "The EMMY trial has made an important contribution to understanding of the safety and potential efficacy of SGLT2 inhibitors following MI. These findings increase our optimism that these drugs may provide clinical benefit to the post-MI population."

[Read the paper here]